Wegovy Is Now the Second FDA-Approved Treatment for MASH Fibrosis

Key Takeaways

The FDA approved the obesity drug Wegovy as a treatment for people with MASH fibrosis.

It’s the second drug approved to treat scarring in people with the advanced fatty liver disease

Experts say patients must improve their diet and exercise habits to see the liver benefits shown in clinical trials.

The Food and Drug Administration has approved Wegovy, a GLP-1 drug for obesity, to treat metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease.

Drugmaker Novo Nordisk received accelerated approval for the drug’s use in people with moderate to advanced liver scarring, alongside a reduced-calorie diet and increased physical activity. Wegovy is now the second FDA-approved treatment for MASH fibrosis.

A Necessary New Treatment for MASH

MASH , f